PER

1.35%

7.5¢ percheron therapeutics limited

For General Information, page-2409

First 2409 Last

Share
Profile

Follow
monti901

964 Posts.

329

23/08/23

16:23

Post #: 69506167
Share

Originally posted by BoomCrashOffera: ↑

I’m wary of treading into medical science comparisons, but some differences between ANP (ATL1102) and CAPR (CAP1002) imo on a cursory analysis.

1. CAP1002 is in phase three (pivotal) trial stage (HOPE-3) and has 4 years of data on their P2 trial (one year blinded with placebo, a gap year and then 2 years of OLE).

2. CAP1002 P2 and P3 trials include placebo group

3. CAP1002 - Intravenous doses every 3 months versus ATL1102 injections every week

4. CAP102 Results include cardio function as well as PUL 2.0. 6 of 9 boys had improved cardio function after two year OLE (open label extension) in P2 trial. ATL1102 is yet to prove it can affect heart function. I recall reading somewhere that this was a challenge with antisense oligonucleotides. Someone with more medical knowledge could correct me here.

5. Correct me if I’m wrong but CAP1002 trials cover both ambulant and non-ambulant boys

6. No toxicity issues and a US pathway well established. In ongoing meetings with FDA that they will soon publish minutes of the latest.

7. They create, own and develop their drugs. No licensing and/or payaway or limit to creating new drugs.

8. They have a distribution agreement in place for US and Japan markets with Nippon Shinyaku.

9. CAPR have 77 employees, 8 directors and 10 scientific advisors.

Apart from the above, ATL1102 could be a better treatment.

Expand

Makes wonder why you are invested in ANP Boom if CAPR is that far ahead? Wouldn’t you be invested with CAPR instead?

ANP Price at posting: 5.2¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

AAI

NYSE-listed Alcoa Corp joins ASX through key JV acquisition

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

OPL

Opyl forms JV with UK and US consortium to bring products to the world

HXL

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

There are more pages in this discussion • 1,118 more messages in this thread...

First 2409 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 7.5¢		Change 0.001(1.35%)		Mkt cap ! $67.61M

Open	High	Low	Value	Volume
7.7¢	7.8¢	7.4¢	$24.63K	325.4K

Buyers (Bids)

No.	Vol.	Price($)
2	142779	7.3¢

Sellers (Offers)

Price($)	Vol.	No.
7.5¢	8181	1

View Market Depth

No.	Vol.	Price($)
2	142779	0.073
2	147362	0.072
2	310000	0.071
4	34299	0.070
2	28980	0.069

Price($)	Vol.	No.
0.075	8181	1
0.078	125476	3
0.079	175123	2
0.080	287231	3
0.081	125000	2

Last trade - 16.10pm 26/07/2024 (20 minute delay)

PER (ASX) Chart

For General Information, page-2409

Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

NYSE-listed Alcoa Corp joins ASX through key JV acquisition

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Geochemical work at Newington picks up gold and copper anomalies for Midas

Opyl forms JV with UK and US consortium to bring products to the world

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

For General Information, page-2409

Top Stories

Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

NYSE-listed Alcoa Corp joins ASX through key JV acquisition

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Geochemical work at Newington picks up gold and copper anomalies for Midas

Opyl forms JV with UK and US consortium to bring products to the world

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News